Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 48

Results For "President"

1685 News Found

Shanghai Argo announces multi-program RNAi licenses with Novartis
News | January 11, 2024

Shanghai Argo announces multi-program RNAi licenses with Novartis

Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.


Deloitte expands Quartz AI suite with Atlas AI for drug discovery
Digitisation | January 11, 2024

Deloitte expands Quartz AI suite with Atlas AI for drug discovery

Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design


Tata 1mg and Vitonnix UK get into an exclusive partnership in India
News | January 10, 2024

Tata 1mg and Vitonnix UK get into an exclusive partnership in India

Launch innovative vitamin sublingual sprays


Bruker acquires Tornado Spectral Systems to expand biopharma PAT product portfolio
Medical Device | January 10, 2024

Bruker acquires Tornado Spectral Systems to expand biopharma PAT product portfolio

Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products


Merck to acquire Harpoon Therapeutics for US$ 680 million
News | January 10, 2024

Merck to acquire Harpoon Therapeutics for US$ 680 million

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors


Lupin launches second edition of Aptivate Champion Run for Kids
News | January 09, 2024

Lupin launches second edition of Aptivate Champion Run for Kids

Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in Aptivate Champion Run


European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer
Drug Approval | January 09, 2024

European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer

TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union


Omniose collaborates with AstraZeneca to research vaccines for serious bacterial diseases
Diagnostic Center | January 07, 2024

Omniose collaborates with AstraZeneca to research vaccines for serious bacterial diseases

Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens


AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan
News | January 07, 2024

AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan

The deal includes upfront payments, milestone payments and ongoing royalties


Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline
Diagnostic Center | January 06, 2024

Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline

Comprehensive clinical development programs being initiated for each investigational candidate